Laboratory of the Swiss HPB and Transplantation Center, Department of Surgery, University Hospital Zürich, Switzerland.
Department of Neuropathology, University Hopital Zürich, Switzerland.
J Hepatol. 2016 Jul;65(1):66-74. doi: 10.1016/j.jhep.2016.02.040. Epub 2016 Mar 3.
BACKGROUND & AIMS: Liver can recover following resection. If tissue loss is too excessive, however, liver failure will develop as is known from the small-for-size-syndrome (SFSS). The molecular processes underlying liver failure are ill-understood. Here, we explored the role and the clinical potential of Nr1i3 (constitutive androstane receptor, Car) in liver failure following hepatectomy.
Activators of Car, various hepatectomies, Car(-/-) mice, humanized CAR mice, human tissue and ex vivo liver slice cultures were used to study Car in the SFSS. Pathways downstream of Car were investigated by in vivo siRNA knockdown.
Excessive tissue loss causing liver failure is associated with deficient induction of Car. Reactivation of Car by an agonist normalizes all features associated with experimental SFSS. The beneficial effects of Car activation are relayed through Foxm1, an essential promoter of the hepatocyte cell cycle. Deficiency in the CAR-FOXM1 axis likewise is evident in human SFSS. Activation of human CAR mitigates SFSS in humanized CAR mice and improves the culture of human liver slices.
Impaired hepatic Car-Foxm1 signaling provides a first molecular characterization of liver that fails to recover after tissue loss. Our findings place deficient regeneration as a principal cause behind the SFSS and suggest CAR agonists may bear clinical potential against liver failure.
The unique regenerative capacity of liver has its natural limits. Following tissue loss that is too excessive, such as through extended resection in the clinic, liver failure may develop. This is known as small-for-size-syndrome (SFSS) and represents the most frequent cause of death due to liver surgery. Here we show that deficient induction of the protein Car, a central regulator of liver function and growth, is a cause of liver failure following extended resection; reactivation of Car through pharmacological means is sufficient to prevent or rescue the SFSS.
肝脏可以在切除后再生。然而,如果组织损失过大,就会像小肝综合征 (SFSS) 那样发展为肝衰竭。肝衰竭的分子过程尚未完全清楚。在这里,我们探讨了 Nr1i3(组成型雄烷受体,Car)在肝切除后肝衰竭中的作用和临床潜力。
使用 Car 的激动剂、各种肝切除术、Car(-/-) 小鼠、人源化 CAR 小鼠、人组织和离体肝切片培养物来研究 SFSS 中的 Car。通过体内 siRNA 敲低研究 Car 下游途径。
导致肝衰竭的过度组织损失与 Car 诱导不足有关。激动剂对 Car 的再激活可使所有与实验性 SFSS 相关的特征正常化。Car 激活的有益作用通过 Foxm1 传递,Foxm1 是肝细胞细胞周期的必需启动子。在人类 SFSS 中也可以看到 CAR-FOXM1 轴的缺陷。在人源化 CAR 小鼠中激活人 CAR 减轻了 SFSS,并改善了人肝切片的培养。
肝内 Car-Foxm1 信号传导受损为肝在组织损失后无法恢复提供了第一个分子特征。我们的发现将再生不足作为 SFSS 背后的主要原因,并表明 CAR 激动剂可能具有针对肝衰竭的临床潜力。
肝脏独特的再生能力有其自身的限制。在组织损失过大的情况下,例如临床上的广泛切除,可能会发展为肝衰竭。这被称为小肝综合征 (SFSS),是肝脏手术后死亡的最常见原因。在这里,我们表明,中央调节肝脏功能和生长的蛋白 Car 的诱导不足是广泛切除后肝衰竭的原因;通过药理学手段再激活 Car 足以预防或挽救 SFSS。